Researchers have shown that Sirt1 can interrupt the progression of DCM by inhibiting oxidative stress, calcium overload, metabolic disorders, and apoptosis by mediating several molecular factors, such as activating peroxisome proliferator-activated receptor gamma-coactivator alpha (PGC-1) and sarcoplasmic reticulum calcium ATPase (SERCA2a) [75]. Here, SIRT1 is linked to metabolic disease.